Zeitschrift für Rheumatologie

, 67:440 | Cite as

Leberwerterhöhung bei rheumatoider Arthritis

Differenzialdiagnostische Überlegungen an einem Fallbeispiel
Kasuistiken
  • 179 Downloads

Zusammenfassung

Leberwerterhöhungen bei Patienten mit rheumatoider Arthritis (RA) können unterschiedliche Ursachen haben. Diese reichen von der Grunderkrankung über Therapiefolgen bis zur (Erst-)Manifestation einer assoziierten Autoimmunerkrankung. Wir stellen den Fall einer 19-jährigen Patientin mit seropositiver RA vor, bei der unter antirheumatischer Therapie mit Adalimumab und Leflunomid nach etwa 9 Monaten ein drastischer Anstieg der Leberenzyme sowie der Cholestaseparameter auftrat. Daraufhin wurde die spezifische Therapie ausgesetzt. Außer der Grunderkrankung und der antirheumatischen Therapie kamen auch eine stattgehabte Behandlung mit Flucloxacillin sowie eine Assoziation zu einer zeitgleich diagnostizierten Zöliakie als mögliche Ursachen der Transaminasenerhöhung in Betracht. Nach mehrfacher Leberbiopsie wurde unter Annahme einer Autoimmunhepatitis mit Prednisolon und Azathioprin behandelt. Hierunter trat eine rasche Normalisierung der Leberwerte ein.

Schlüsselwörter

Leberwerterhöhung Rheumatoide Arthritis Differenzialdiagnose 

Elevated liver enzymes in rheumatoid arthritis

Differential diagnostic considerations based on a case report

Abstract

Elevated liver enzymes in patients with rheumatoid arthritis may have various causes. These can range from the rheumatic disease itself, the anti-rheumatic medication or be the manifestation of an associated autoimmune disease. We present the case of a 19-year-old female with known seropositive rheumatoid arthritis who developed severe liver damage after 9 months of anti-rheumatic therapy with leflunomide and adalimumab. Both drugs were stopped. In addition to the underlying disease and the specific anti-rheumatic drugs, a temporary therapy with flucloxacillin as well as an association with newly diagnosed celiac disease had to be considered as possible causes of elevated liver enzymes. Following repeated liver biopsy, autoimmune hepatitis was assumed and prednisolone and azathioprine were initiated. Elevated liver enzymes and bilirubin rapidly returned to normal values.

Keywords

Elevated liver enzymes Rheumatoid arthritis Differential diagnosis 

Literatur

  1. 1.
    Alderman CP (1996) Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother 30: 55–61PubMedGoogle Scholar
  2. 2.
    Björnsson E, Jerlstad P, Bergqvist A, Olsson R (2005) Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 40: 1095–1101PubMedCrossRefGoogle Scholar
  3. 3.
    Cannon GW, Kremer JM (2004) Leflunomide. Rheum Dis Clin North Am 30: 295–309PubMedCrossRefGoogle Scholar
  4. 4.
    Davison S (2002) Coeliac disease and liver dysfunction. Arch Dis Child 87: 293–296PubMedCrossRefGoogle Scholar
  5. 5.
    Dechant C, Schauenberg P, Antoni CE et al. (2004) Langzeitergebnisse einer TNF-Blockade beim Morbus Still im Erwachsenenalter. DMW 129: 1308–1312Google Scholar
  6. 6.
    Fairley CK, McNeil JJ, Desmond P et al. (1993) Risk factors for development of flucloxacillin associated jaundice. BMJ 306: 233–235PubMedCrossRefGoogle Scholar
  7. 7.
    Gause AM, Schöning C (2007) Manifestation einer auoimmunen Lebererkrankung unter Adalimumab. Z Rheumatol (Suppl) 1: 54Google Scholar
  8. 8.
    Germano V, Picchianti Diamanti A, Baccano G et al. (2005) Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64: 1519–1520PubMedCrossRefGoogle Scholar
  9. 9.
    Hartleb M, Biernat L, Kochel A (2002) Drug-induced liver damage a three-year study of patients from one gastroenterological department. Med Sci Monit 8: 292–296Google Scholar
  10. 10.
    Iwai M, Harada Y, Ishii M et al. (2003) Autoimmune hepatitis in a patient with systemic lupus erythematosus. Clin Rheumatol 22: 234–236PubMedCrossRefGoogle Scholar
  11. 11.
    Katayama Y, Kohriyama K, Kirizuka K et al. (2000) Sjögren’s syndrome complicated with autoimmune hepatitis and antiphospholipid antibody syndrome. Intern Med 39: 73–76PubMedCrossRefGoogle Scholar
  12. 12.
    Koek GH, Stricker BH, Blok AP et al. (1994) Flucloxacillin-associated hepatic injury. Liver 14: 225–229PubMedGoogle Scholar
  13. 13.
    Li EK, Tam LS, Tomlinson B (2004) Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 26: 447–459PubMedCrossRefGoogle Scholar
  14. 14.
    Lohse AW, Hennes E (2007) Diagnostic criteria for autoimmune hepatitis. Hepatol Res (Suppl 3) 37: 509Google Scholar
  15. 15.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434–438PubMedGoogle Scholar
  16. 16.
    Misdraji J, Thiim M, Graeme-Cook FM (2004) Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 28: 471–478PubMedCrossRefGoogle Scholar
  17. 17.
    Ramos-Casals M, Brito-Zerón P, Munoz S et al. (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242–251Google Scholar
  18. 18.
    Rubio-Tapia A, Murray JA (2007) The liver in celiac disease. Hepatology 46: 1650–1658PubMedCrossRefGoogle Scholar
  19. 19.
    Russmann S, Kaye JA, Jick SS, Jick H (2005) Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 60: 76–82PubMedCrossRefGoogle Scholar
  20. 20.
    Scheinfeld N (2005) Adalimumab: a review of side effects. Expert Opin Drug Saf 4: 637–641PubMedCrossRefGoogle Scholar
  21. 21.
    Sema K, Takei M, Uenogawa K et al. (2005) Felty’s syndrome with chronic hepatitis and compatible autoimmune hepatitis: a case presentation. Intern Med 44: 335–341PubMedCrossRefGoogle Scholar
  22. 22.
    Tobon GJ, Canas C, Jaller JJ et al. (2007) Serious liver disease induced by infliximab. Clin Rheumatol 26: 578–581PubMedCrossRefGoogle Scholar
  23. 23.
    Turner IB, Eckstein RP, Riley JW, Lunzer MR (1989) Prolonged hepatic cholestasis after flucloxacillin therapy. Med J Aust 151: 701–705PubMedGoogle Scholar
  24. 24.
    Putte LBA van de, Rau R, Breedveld FC et al. (2003) Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 62: 1168–1177PubMedCrossRefGoogle Scholar
  25. 25.
    Wiegand J, Mössner J, Tillmann HL (2007) Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Internist (Berl) 48: 154–163Google Scholar
  26. 26.
    Wiegard C, Lohse AW (2005) Leber und Rheuma. Z Rheumatol 64: 26–31PubMedCrossRefGoogle Scholar
  27. 27.
    Yatsuji S, Hashimoto E, Kaneda H et al. (2005) Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? J Gastroenterol 40: 1130–1138PubMedCrossRefGoogle Scholar
  28. 28.
    Yeung E, Wong FS, Wanless IR et al. (2003) Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 127: 1493–1497PubMedGoogle Scholar
  29. 29.
    Youssef WI, Tavill AS (2002) Connective tissue diseases and the liver. J Clin Gastroenterol 35: 345–349PubMedCrossRefGoogle Scholar
  30. 30.
    Zeniya M, Watanabe F, Morizane T et al. (2005) Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model. J Gastroenterol 40: 1148–1154PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  1. 1.Fachklinik für Onkologie und RheumatologieKlinik „Am Kurpark“Bad KissingenDeutschland
  2. 2.Innere Medizin I GastroenterologieSt. Elisabeth Krankenhaus GmbHBad KissingenDeutschland

Personalised recommendations